(AOF) – Valneva, a company specializing in vaccines, announced new positive results in adolescents for the pivotal Phase 3 study of its single-dose vaccine against the chikungunya virus. Following an initial analysis of study VLA1553-321 performed on day 29 post-vaccination, the most recent analysis assessed safety and immunogenicity six months (day 180) post-vaccination with a single dose of the vaccine.
The day 180 results confirmed the previously announced positive initial immunogenicity and safety data in adolescents, and are expected to allow the company to submit an application for expansion of use in adolescents aged 13 to 17 years. .
These results should also allow the approval of the vaccine in Brazil, which would then constitute the first marketing authorization for use in an endemic population.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.